Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nexalin TechnologyNXL +0.18%38 FCF Yield % is -86.59 as of Aug. 20, 2026. GuruFocus rates NXL with a GF Score™ of 38/100 and a GF Value™ of $0.66 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 849 Medical Devices & Instruments companies, Nexalin Technology ranks worse than 94.23% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Nexalin Technology FCF Yield % Related Terms
Nexalin Technology FCF Yield % Historical Data
* Premium members only.
The historical data trend for Nexalin Technology's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Nexalin Technology's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nexalin Technology FCF Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nexalin Technology's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Nexalin Technology's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nexalin Technology (NXL) has a FCF Yield % of -86.59 as of Aug. 20, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Nexalin Technology and its competitors. According to the industry distribution chart, Nexalin Technology ranks #800 out of 849 companies in the Medical Devices & Instruments industry, placing it in the top 94.2%.
Is Nexalin Technology's FCF Yield % too high?
Nexalin Technology's current FCF Yield % is -86.59. Based on the distribution chart, Nexalin Technology ranks #800 out of 849 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Nexalin Technology has a GF Score™ of 38/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Nexalin Technology's FCF Yield % compare to ICCM and ADGM?
According to the Medical Devices & Instruments industry distribution chart, Nexalin Technology ranks #800 out of 849 companies for FCF Yield %. This places Nexalin Technology in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Medical Devices & Instruments company?
A good FCF Yield % depends on the Medical Devices & Instruments industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Nexalin Technology and its competitors. Nexalin Technology's current FCF Yield % is -86.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nexalin Technology stock overvalued right now?
Based on GuruFocus' analysis, Nexalin Technology (NXL) is currently considered Possible Value Trap. The stock's GF Value™ is $0.66, compared to a current price of $0.33 — trading 49.6% below its estimated fair value. The current FCF Yield % is -86.59. Nexalin Technology's overall GF Score™ is 38/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Nexalin Technology (NXL), the current FCF Yield % is -86.59 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nexalin Technology (NXL) Overvalued in 2026?
Based on GuruFocus' analysis, Nexalin Technology stock appears to be undervalued.
The current stock price of $0.33 is trading 49.6% below its estimated GF Value™ of $0.66.
GuruFocus considers Nexalin Technology to be Possible Value Trap.
Key valuation signals for NXL:
FCF Yield %: -86.59
GF Value™: $0.66 vs. price of $0.33 (49.6% below fair value)
No single metric tells the full story. See the NXL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.
38GF Score
Get the complete analysis for NXL
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NXL has been successfully added to your 
